Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial

Edgar Turner Overton  
*University of Alabama, Birmingham*

Steven J. Lawrence  
*Washington University School of Medicine in St. Louis*

Eva Wagner  
*Bavarian Nordic GmbH*

Katrin Nopora  
*Bavarian Nordic GmbH*

Siegfried Rosch  
*Bavarian Nordic GmbH*

See next page for additional authors

Follow this and additional works at:  [https://digitalcommons.wustl.edu/open_access_pubs](https://digitalcommons.wustl.edu/open_access_pubs)

Recommended Citation

Overton, Edgar Turner; Lawrence, Steven J.; Wagner, Eva; Nopora, Katrin; Rosch, Siegfried; Young, Philip; Schnidt, Darja; Kreusel, Christian; De Carli, Sonja; Meyer, Thomas P.; Weidenthaler, Heinz; Samy, Nathaly; and Chaplin, Paul, "Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial." *PLoS One.* 13,4. e0195897. (2018).  
[https://digitalcommons.wustl.edu/open_access_pubs/6954](https://digitalcommons.wustl.edu/open_access_pubs/6954)
RESEARCH ARTICLE

Immunogenicity and safety of three consecutive production lots of the non-replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial

Edgar Turner Overton, Steven J. Lawrence, Eva Wagner, Katrin Nopora*, Siegfried Rösch, Philip Young, Darja Schmidt, Christian Kreusel, Sonja De Carli, Thomas P. Meyer, Heinz Weidenthaler, Nathaly Samy, Paul Chaplin

1 Division of Infectious Diseases, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, United States of America, 2 Division of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri, United States of America, 3 Bavarian Nordic GmbH, Martinsried, Germany

* kan@bavarian-nordic.com

Abstract

Background

Modified Vaccinia Ankara (MVA) is a live, viral vaccine under advanced development as a non-replicating smallpox vaccine. A randomised, double-blind, placebo-controlled phase III clinical trial was conducted to demonstrate the humoral immunogenic equivalence of three consecutively manufactured MVA production lots, and to confirm the safety and tolerability of MVA focusing on cardiac readouts.

Methods

The trial was conducted at 34 sites in the US. Vaccinia-naive adults aged 18-40 years were randomly allocated to one of four groups using a 1:1:1:1 randomization scheme. Subjects received either two MVA injections from three consecutive lots (Groups 1-3), or two placebo injections (Group 4), four weeks apart. Everyone except personnel involved in vaccine handling and administration was blinded to treatment. Safety assessment focused on cardiac monitoring throughout the trial. Vaccinia-specific antibody titers were measured using a Plaque Reduction Neutralization Test (PRNT) and an Enzyme-Linked Immunosorbent Assay (ELISA). The primary immunogenicity endpoint was Geometric Mean Titers (GMTs) after two MVA vaccinations measured by PRNT at trial visit 4. This trial is registered with ClinicalTrials.gov, number NCT01144637.

Results

Between March 2013 and May 2014, 4005 subjects were enrolled and received at least one injection of MVA (n = 3003) or placebo (n = 1002). The three MVA lots induced equivalent antibody titers two weeks after the second vaccination, with seroconversion rates of 99.8%...
reimbursed the clinical trial investigators (i.e. ETO and SJL) for their efforts. Bavarian Nordic provided support in form of salaries for authors EW, KN, SR, PY, DS, CK, SDC, TPM, HW, NS and PC. The statistical analysis plan was written by PY (Bavarian Nordic). Data collection, management and analysis were performed by Chiltern International Inc. (Bristol, TN). The specific roles of the authors are articulated in the “author contributions” section. Bavarian Nordic did not have any additional role in the data collection and analysis, decision to publish or preparation of the manuscript.

**Competing interests:** I have read the journal’s policy and the authors of this manuscript have the following competing interests: The trial was funded by the Biomedical Advanced Research and Development Authority (BARDA, [http://www.phe.gov/about/BARDA/Pages/default.aspx](http://www.phe.gov/about/BARDA/Pages/default.aspx)). Bavarian Nordic was the sponsor receiving the fund (BARDA Contract No.: HHSO100200700034C). Bavarian Nordic reimbursed the clinical trial investigators and the design and conduct of the trial were managed by Bavarian Nordic A/S. Authors EW, KN, SR, PY, DS, CK, SDC, TPM, HW, NS and PC were employed by Bavarian Nordic GmbH, the manufacturer of MVA-BN. Patents relevant to this study are part of the supporting information as there are too many to list. The statistical analysis plan was written by PY. Data collection, management and analysis were performed by Chiltern International Inc. (Bristol, TN). The specific roles of the authors are articulated in the “author contributions” section. There are no further patents, marketed products or products in development to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.

**Trial registration**
ClinicalTrials.gov [NCT01144637](https://clinicaltrials.gov/ct2/show/NCT01144637)

**Introduction**
Despite the eradication of smallpox in 1980 [1], the risk of reoccurrence still remains due to its potential use in biological warfare [2, 3]. The limited immunity in the general population due to the discontinuation of routine vaccination programs raises the need for contingency plans involving vaccine stockpiles. However, current stockpiles comprise traditional replicating vaccines that are contraindicated for up to 25% of the population (e.g. individuals with impaired immune systems or eczematous skin disease, as well as their contacts) [4]. Furthermore, a series of cardiac adverse events, including myo-/pericarditis, have been observed in close temporal relationship to the administration of replicating smallpox vaccines such as ACAM2000 [5–9]. Their use in a pre-emergency situation is thus restricted to high-risk populations (e.g. military personnel), disregarding other relevant groups such as first-line responders. Safer vaccines are thus needed to encompass a wider population. MVA is a live, highly attenuated Modified Vaccinia Ankara virus currently in advanced clinical development as a non-replicating smallpox vaccine and is considered to be a safer alternative over replicating smallpox vaccines [10].

MVA has demonstrated protective efficacy in animal models, including non-human primates [11], as well as robust immunogenicity and a good safety profile in healthy individuals, including elderly and at-risk populations usually contraindicated to receive replicating smallpox vaccines [people infected with human immunodeficiency virus (HIV), diagnosed with atopic dermatitis (AD), or under immune suppressive treatment] [12–17]. Moreover, MVA induces peak antibody responses comparable to the ones elicited by the replicating smallpox vaccine Dryvax® in healthy subjects. Prior MVA vaccination inhibits the replication of vaccinia virus (Dryvax®) in the skin [18]. In order to further address the potential efficacy of MVA as a reliable inoculation strategy against smallpox, clinical trials performed so far have included vaccinia-naïve as well as vaccinia-experienced subjects [12,13,15,19]. In 2010, MVA was granted a pre-emergency use authorization status in the U.S. for the vaccination of vulnerable populations contraindicated to receive replicating smallpox vaccines, such as HIV-infected individuals and subjects with atopic dermatitis (AD). MVA has been licensed in the European Union (EU) and Canada since 2013 (trade name outside EU IMVAMUNE®; invented name in the EU IMVANEX®) [17,18,20,21].
The objectives of the phase III trial reported here were to demonstrate the equivalence of three consecutive MVA production lots in terms of induced antibody titers, and to confirm the favorable cardiac safety and tolerability profile of MVA.

**Methods**

**Trial design and participants**

This randomised, double-blind, placebo-controlled Phase III trial was conducted at 34 sites in the US between March 18, 2013 and May 23, 2014. The study was approved by the following Institutional Review Boards: Quorum Review IRB, 1601 5th Avenue, Seattle, WA; Washington University in St. Louis Human Research Protective Office, 600 South Euclid Avenue, St. Louis, MO; Marshall University IRB #1 / Office of Research Integrity, 401 11th Street, Huntington, WV; The University of Alabama at Birmingham IRB for Human Use, 701 20th Street South, Birmingham, AL.

Healthy, vaccinia-naïve, women and men aged 18-40 years were randomised into four groups: Groups 1 to 3 received two subcutaneous (s.c.) MVA injections from three different consecutively manufactured vaccine lots at weeks 0 and 4. Group 4 received two s.c. placebo injections in the same time interval. The active trial period (8-10 weeks) comprised five visits. A phone follow-up (FU) visit was performed 26 weeks after the second injection. The trial was conducted according to ICH-GCP standards and the principles of the Declaration of Helsinki. The protocol was approved by independent review committees for each site and all subjects provided written informed consent prior to participation.

**Randomisation and blinding**

Treatment was assigned at trial visit 1 after re-confirmation of the subject’s eligibility. The randomisation scheme was 1:1:1:1 (3 MVA groups and 1 placebo group). Randomisation was stratified by clinical trial site. The unblinded trial statistician generated randomisation sequences (block randomisation with block size of eight) and the unblinded clinical trial staff assigned each participant to a treatment group using a secure interactive web response system. Everyone except personnel performing randomization, vaccine handling and administration, remained blinded to treatment throughout the study.

**Procedures**

The MVA bulk drug substance was produced at Bavarian Nordic A/S (Kvistgard, Denmark) according to cGMP standard and the final drug product was filled, formulated and labelled at IDT Biologika GmbH (Dessau-Roßlau, Germany). One dose (0.5 mL) of the liquid frozen formulation had a nominal virus titre of 1 x 10^8 TCID_{50}. Placebo consisted of the vaccine formulation buffer, Tris-buffered saline (TBS), provided in liquid aliquots. One placebo dose (0.5 mL) contained 0.605 mg tris (hydroxymethyl)-amino methane and 4.09 mg sodium chloride.

To evaluate the safety of MVA, solicited and unsolicited AEs were recorded at all visits. Serious Adverse Events (SAEs) were monitored up to the six months phone FU visit. Solicited AEs constituted a set of pre-defined, expected local reactions (erythema, swelling, pain, itching, and induration) and systemic symptoms (pyrexia, headache, myalgia, nausea, fatigue and chills). All solicited AEs were recorded on a memory aid during an 8-day period following each injection. Treatment-emergent unsolicited AEs were events not included in the memory aid and reported by the subject within a 29-day period after each injection. Safety laboratory tests were performed at screening and two weeks after each injection. Troponin I testing and electrocardiograms (ECG) were performed at screening and two weeks after the first injection.
If clinically indicated, additional safety measures could be taken at any other scheduled or unscheduled visit. Any cardiac symptoms developed since the first injection, clinically significant ECG changes and Troponin I elevations ≥2 x upper limit of normal (ULN) were defined as AEs of special interest (AESIs). Any subject developing an AESI was requested to return to the clinical trial site in order to perform a thorough work-up, physical and cardiac examination comprising ECG, cardiac enzymes and/or echocardiogram. If necessary, further diagnostic tests and regular follow-ups could be performed until complete resolution or stabilization.

Blood for immunogenicity serum collection was drawn at baseline prior to the first injection (week 0) and two weeks after the second injection (week 6). These time points are based on results obtained during the phase I and II development program, in which peak antibody titers were consistently observed two weeks after the second vaccination in vaccinia-naïve subjects [15,16,19–22]. PRNT and ELISA were performed as previously described with the following modifications: For the ELISA, a cut off value of 0.35 was used. For the PRNT, the neutralization was performed in Dulbecco’s modified Eagle’s medium/0.1% human serum albumin and the detection limit was a titer of 2 [15]. Seroconversion was defined as the appearance of titers equal to or higher than the detection limit for subjects seronegative at baseline, or as an at least 2-fold increase over pre-existing titers for subjects tested positive at baseline.

**Objectives**

The primary objective was to assess the equivalence of three consecutively produced MVA lots by PRNT. The secondary objectives were to assess uncommon adverse reactions, with a particular focus on cardiac signs and symptoms indicating myo-/pericarditis, and to compare their frequency to those observed after placebo. Additionally, vaccinia-specific humoral immune evaluations utilizing an ELISA and a correlation analysis between total and neutralizing antibody titers were performed.

**Criteria for evaluation**

**Primary immunogenicity endpoint:**
GMTs after two MVA vaccinations measured by PRNT at trial visit 4.

**Secondary immunogenicity endpoints:**
1. GMTs after two MVA vaccinations measured by ELISA at trial visit 4.
2. Vaccinia-specific PRNT and ELISA seroconversion rates at trial visit 4
3. Pearson Correlation Coefficient between the log_{10} transformed PRNT titers and the log_{10} transformed ELISA titers at trial visit 4.

**Secondary safety and reactogenicity endpoints:**
1. Occurrence, relationship and intensity of any Serious Adverse Event (SAE) at any time during the trial.
2. Occurrence, relationship and intensity of any cardiac sign or symptom indicating a case of myo-/pericarditis
3. Occurrence of any Grade 3 or 4 Adverse Events (AEs) probably, possibly or definitely related to the trial vaccine within 28 days after vaccination.
4. Occurrence, relationship and intensity of unsolicited non-serious AEs within 28 days after each vaccination.
5. Occurrence, relationship and intensity of solicited local AEs (erythema, swelling, pain, itching, and induration) during the 8-day period (day of vaccination and the following seven days) after each vaccination.

6. Occurrence, relationship, intensity and duration of solicited general AEs (pyrexia, headache, myalgia, nausea, fatigue and chills) during the 8-day period (day of vaccination and the following seven days) after each vaccination.

**Datasets analysed.** The Full Analysis Set (FAS) consisted of all randomized subjects who received at least one vaccination and for whom any data were available. For all analyses using the FAS, subjects were summarized according to the treatment that they received.

The Immunogenicity Analysis Set (IAS) was a subset of the FAS comprised of the first 700 randomized subjects from each group.

The Per Protocol Set (PPS) consisted of all subjects present in the IAS who received both vaccinations, completed Visits 1, 3, and 4, and adhered to all protocol conditions. Subjects with only minor protocol deviations were included in this dataset.

**Statistical analysis**

Statistical analyses were performed using SAS version 9.1 (SAS Institute, Cary, NC).

Assuming a significance level of 5%, an analyzable sample size of 600 per group for the PPS, and an expected log_{10} titer SD of 0.85 in all groups receiving MVA for the PRNT, the primary hypothesis of the PRNT GMT at Visit 4 (i.e., after two MVA vaccinations) has a power of > 80% to show equivalence for all three MVA groups, using an equivalence margin of Δ = 0.301 on the log_{10} scale. In order to account for a dropout rate of about 15%, which has been observed in previous MVA trials, serum collection was scheduled for a total of 700 subjects in each group.

To allow a proper safety analysis, 300 additional subjects were enrolled in each group to ensure that a total of ~1,000 subjects per group were available, giving a combined MVA safety population of 3,000 subjects. With this sample size the trial had a 95% chance of detecting any uncommon AEs, i.e., AEs with an incidence of at least 1/1,000.

Immunogenicity analyses were primarily ran on the PPS and the IAS.

The PRNT and ELISA titers were transformed into log_{10} titers for the calculation of geometric means and 95% confidence intervals (CIs). Titers below the detection limit were assigned a value of 1 for GMT calculation.

For lot equivalence, a two-sided 95% CI was calculated using the differences of the means of the log_{10}-transformed post baseline titers between pairs of lots. Equivalence among the three lots was demonstrated if for each pair of lots, the two-sided 95% CI for the log_{10} PRNT mean was between -0.301 and 0.301, i.e., if the PRNT GMT ratio of each pair of lots was between 0.5 and 2.0. For the ELISA, the two-sided 95% CI was -0.176 and 0.176, i.e. the ELISA GMT ratio was between 0.66 and 1.5.

For the PRNT and ELISA correlation, Pearson’s correlation coefficient (with associated CI) between log_{10} titers measured by both assays was calculated per group and for Groups 1–3 combined along with the associated p-values and 95% CIs.

The trial was overseen by an independent data safety monitoring board (DSMB; 4 meetings) and is registered with ClinicalTrials.gov, number NCT01144637.

**Results**

A total of 5357 volunteers aged 18–40 years were screened, of whom 4005 were eligible for enrolment. All eligible subjects received at least one injection, had data available for analysis
and were included in the FAS. Of these 4005 subjects, 2829 were included in the IAS. Of the 2829 subjects in the IAS, 2549 were eligible for the PPS (Fig 1).

There were no statistically significant differences for any demographic characteristics among treatment groups (Table 1).

Vaccinations were generally well tolerated. Higher proportions of subjects vaccinated with MVA experienced solicited local AEs compared to Placebo (Group 1: 892/985 [90.6%]; Group 2: 865/976 [88.6%]; Group 3: 879/982 [89.5%] and Placebo: 344/980 [35.1%]) as well as solicited general AEs compared to Placebo (Group 1: 588/985 [59.7%]; Group 2: 577/976 [59.1%]; Group 3: 589/982 [60.0%] and Placebo: 381/980 [38.9%]).

Table 2 presents an overview of the incidence of all unsolicited AEs. A total of 180 (6.0%) subjects in the combined MVA groups (Groups 1–3) reported at least 1 unsolicited AE that was considered by the investigator to be (at least possibly) related to the trial vaccine. A smaller proportion of subjects in the placebo group (2.9%) experienced related unsolicited AEs (p = 0.0001).

Injection site induration and injection site hematoma were the only unsolicited AEs experienced by more than 1% of the subjects and mostly occurred after the first vaccine administration (data not shown).

A total of 18/3003 MVA-vaccinated subjects (0.6%) and 3/1002 placebo-vaccinated subjects (0.3%) were withdrawn from the trial due to an AE, most of which were assessed as unrelated or unlikely related to the trial vaccine, and had a mild to moderate intensity. Four subjects...
receiving MVA were withdrawn due to AEs corresponding to arthralgia, bundle branch block, pericarditis or pruritus, assessed as possibly related to the trial vaccine. The occurrence of two life-threatening events (a suicide and a suicide attempt) leading to withdrawal of subjects receiving MVA was assessed as unrelated to the vaccine. One subject in the placebo group experienced a seizure in temporal relation to the trial vaccination. This possibly related SAE of moderate intensity was the only Suspected Unexpected Serious Adverse Reaction (SUSAR) occurring during the trial. Injection site reactions and an AE of dizziness leading to withdrawal were assessed as definitely related to the vaccine. Overall, the AE safety profile across the three MVA groups was similar (Table 2).

A small proportion of subjects (< 1%) in the placebo group and the combined MVA groups experienced SAEs (p > 0.9999).

Table 1. Demographic data (FAS, n = 4005).

<table>
<thead>
<tr>
<th>Group</th>
<th>Group 1 (Lot 1) (n = 999)</th>
<th>Group 2 (Lot 2) (n = 1005)</th>
<th>Group 3 (Lot 3) (n = 999)</th>
<th>Groups 1–3 (n = 3003)</th>
<th>Group 4 (Placebo) (n = 1002)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age [years]</td>
<td>Mean 28</td>
<td>27</td>
<td>28</td>
<td>28</td>
<td>28</td>
</tr>
<tr>
<td></td>
<td>SD 6-3</td>
<td>6-2</td>
<td>6-3</td>
<td>6-3</td>
<td>6-4</td>
</tr>
<tr>
<td>Height [cm]</td>
<td>Mean 170</td>
<td>171</td>
<td>171</td>
<td>171</td>
<td>171</td>
</tr>
<tr>
<td></td>
<td>SD 9-6</td>
<td>10-1</td>
<td>9-6</td>
<td>9-7</td>
<td>10-1</td>
</tr>
<tr>
<td>Weight [kg]</td>
<td>Mean 76</td>
<td>77</td>
<td>77</td>
<td>77</td>
<td>76</td>
</tr>
<tr>
<td></td>
<td>SD 14-8</td>
<td>15-5</td>
<td>15-4</td>
<td>15-2</td>
<td>15-8</td>
</tr>
<tr>
<td>Gender</td>
<td>Male 473 (47%)</td>
<td>478 (48%)</td>
<td>505 (51%)</td>
<td>1456 (48%)</td>
<td>463 (46%)</td>
</tr>
<tr>
<td></td>
<td>Female 526 (53%)</td>
<td>527 (52%)</td>
<td>494 (49%)</td>
<td>1547 (52%)</td>
<td>539 (54%)</td>
</tr>
<tr>
<td>Ethnicity</td>
<td>Hispanic/Latino 119 (12%)</td>
<td>119 (12%)</td>
<td>108 (11%)</td>
<td>346 (12%)</td>
<td>109 (11%)</td>
</tr>
<tr>
<td></td>
<td>Non-Hispanic/Latino 880 (88%)</td>
<td>886 (88%)</td>
<td>890 (89%)</td>
<td>2656 (88%)</td>
<td>893 (89%)</td>
</tr>
<tr>
<td>Race</td>
<td>White/Caucasian 773 (78%)</td>
<td>790 (79%)</td>
<td>765 (77%)</td>
<td>2328 (77%)</td>
<td>773 (77%)</td>
</tr>
<tr>
<td></td>
<td>Black/African American 172 (17%)</td>
<td>165 (16%)</td>
<td>191 (19%)</td>
<td>528 (18%)</td>
<td>184 (18%)</td>
</tr>
<tr>
<td></td>
<td>Oriental/Asian 24 (2%)</td>
<td>17 (2%)</td>
<td>18 (2%)</td>
<td>59 (2%)</td>
<td>19 (2%)</td>
</tr>
<tr>
<td></td>
<td>Other 30 (3%)</td>
<td>33 (3%)</td>
<td>25 (2%)</td>
<td>88 (3%)</td>
<td>26 (3%)</td>
</tr>
</tbody>
</table>

Data for gender, ethnicity and race are n (%), SD = standard deviation.

https://doi.org/10.1371/journal.pone.0195897.t001

Table 2. Overview of unsolicited adverse events per subject (FAS, n = 4005).

<table>
<thead>
<tr>
<th>SAE</th>
<th>Group 1 (Lot 1) (n = 999)</th>
<th>Group 2 (Lot 2) (n = 1005)</th>
<th>Group 3 (Lot 3) (n = 999)</th>
<th>Groups 1–3 (n = 3003) p-value</th>
<th>Group 4 (Placebo) (n = 1002)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAE</td>
<td>11 (1-1)</td>
<td>7 (0-7)</td>
<td>7 (0-7)</td>
<td>25 (0-8) p = 1.0000</td>
<td>8 (0-8)</td>
</tr>
<tr>
<td>At least possibly related SAE</td>
<td>0 (0-0)</td>
<td>0 (0-0)</td>
<td>0 (0-0)</td>
<td>0 (0-0) p = 0.2502</td>
<td>1 (0-1)</td>
</tr>
<tr>
<td>AESI</td>
<td>2 (0-2)</td>
<td>5 (0-5)</td>
<td>1 (0-1)</td>
<td>8 (0-3) p = 0.4654</td>
<td>1 (0-1)</td>
</tr>
<tr>
<td>At least possibly related AESI</td>
<td>0 (0-0)</td>
<td>1 (0-1)</td>
<td>1 (0-1)</td>
<td>2 (0-1) p = 1.0000</td>
<td>0 (0-0)</td>
</tr>
<tr>
<td>Unsolicited AE</td>
<td>199 (19-9)</td>
<td>238 (23-7)</td>
<td>223 (22-3)</td>
<td>660 (22-0) p = 0.0400</td>
<td>189 (18-9)</td>
</tr>
<tr>
<td>At least possibly related unsolicited AE</td>
<td>54 (5-4)</td>
<td>59 (5-9)</td>
<td>67 (6-7)</td>
<td>180 (6-0) p&lt;0.0001</td>
<td>29 (2-9)</td>
</tr>
<tr>
<td>At least possibly related unsolicited AE Grade0020030 ≥ 3</td>
<td>2 (0-2)</td>
<td>2 (0-2)</td>
<td>2 (0-2)</td>
<td>6 (0-2) p = 0.6882</td>
<td>1 (0-1)</td>
</tr>
<tr>
<td>AE leading to withdrawal from trial</td>
<td>5 (0-6)</td>
<td>9 (0-8)</td>
<td>4 (0-5)</td>
<td>18 (0-6) p = 0.3202</td>
<td>3 (0-3)</td>
</tr>
</tbody>
</table>

Data are n (%)  
* One subject in Group 1 committed suicide 19 days after receiving the first injection. The investigator assessed this death as unrelated to treatment.  
# p-value calculated using Fisher’s exact test comparing the incidences in the combined Groups 1–3 versus Group 4

https://doi.org/10.1371/journal.pone.0195897.t002
A total of 8/3003 subjects (0.3%) in the combined MVA groups experienced AESI compared to one subject in the placebo group (Table 2). Two subjects with elevated Troponin I values (0.13 ng/mL and 0.14 ng/mL) and no abnormal ECG findings returned to normal levels upon retest. Neither was deemed as related to vaccine. Furthermore, five subjects (four in the MVA groups and one in the placebo group) were referred to a cardiologist for evaluation without apparent indication of cardiac toxicity.

Two out of the 3003 MVA-vaccinated subjects (0.1%) experienced AESI related to MVA (Table 2): one in Group 2 exhibited a right bundle branch block in the ECG and another in Group 3 experienced symptoms indicating possible acute pericarditis according to protocol criteria (chest pain worsening when lying down) (Table 3). A thorough cardiac examination, including auscultation, ECG, Troponin I testing and echocardiography did not confirm the diagnosis. The echocardiography did not reveal any signs of pericardial effusion, pericardial rub, ECG changes suggestive of pericarditis, Troponin I increase or decreased exercise capacity. A detailed laboratory examination revealed a positive serology for Coxsackie B virus in temporal relation to the reported chest pain, suggesting a possible acute viral infection as the potential cause of the symptoms.

No subjects in the placebo group experienced AESI considered related to trial vaccine. All AESIs, except a tachycardia experienced by a subject in Group 2, occurred after the first vaccination.

Immunogenicity data for the PPS are shown in Table 4. Similar results were obtained for the IAS. Comparable baseline titers were observed amongst the groups (PRNT: GMT of 1.0 for all groups; ELISA: GMT ranging from 1.1 to 1.3; data not shown) indicating no baseline immunity to smallpox. Two weeks after the second vaccination, vaccinia-specific neutralizing (PRNT) titers had risen to 110^7, 110^5 and 117^2 in Groups 1, 2 and 3 respectively, while the placebo Group had a GMT of 1.0. For total antibodies, ELISA GMT values of 901.0, 794.4 and 946.7 were observed for Groups 1, 2 and 3 respectively, with a GMT of 1.1 in the placebo Group. In both the PRNT and ELISA, ≥99.5% of subjects had seroconverted two weeks after the second vaccination across all MVA groups, with 1.4% (PRNT) and 2.0% (ELISA) of subjects meeting the criteria for seroconversion in the placebo group. Equivalence was statistically proven with a ratio of 1.10, 0.94 and 0.86 in the PRNT for Group 1 / Group 2, Group 1 / Group 3 and Group 2 / Group 3 respectively, meeting the trial primary endpoint. Similar ratios (1.13, 0.95 and 0.84) were determined through ELISA for the respective group pairs (Table 4).

<table>
<thead>
<tr>
<th>Table 3. Adverse events of special interest (FAS, n = 4005).</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Preferred term</strong></td>
</tr>
<tr>
<td>------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>Group 1 (Lot 1)</strong></td>
</tr>
<tr>
<td>Troponin I increase ≥ 2 x ULN</td>
</tr>
<tr>
<td>Wolff-Parkinson-White Syndrome</td>
</tr>
<tr>
<td><strong>Group 2 (Lot 2)</strong></td>
</tr>
<tr>
<td>Troponin I increase ≥ 2 x ULN</td>
</tr>
<tr>
<td>Supraventricular extrasystoles</td>
</tr>
<tr>
<td>Bundle branch block right</td>
</tr>
<tr>
<td>Tachycardia</td>
</tr>
<tr>
<td>ECG ST Segment abnormal</td>
</tr>
<tr>
<td><strong>Group 3 (Lot 3)</strong></td>
</tr>
<tr>
<td>Pericarditis</td>
</tr>
<tr>
<td><strong>Group 4 (Placebo)</strong></td>
</tr>
<tr>
<td>Bundle branch block right</td>
</tr>
</tbody>
</table>

https://doi.org/10.1371/journal.pone.0195897.t003
PRNT and ELISA titers were significantly correlated two weeks after the second vaccination in all groups (p < 0.0001, data not shown).

**Discussion**

This phase III trial was designed according to the recommendations issued by the US FDA to commercialize a non-replicating smallpox vaccine. The results demonstrate a consistent MVA manufacturing process and confirm the favorable cardiac safety profile of MVA in a large population.

Comparable vaccinia-specific PRNT GMT values were observed two weeks following the second vaccination (week 6) in the PPS, demonstrating the equivalence of three consecutively produced MVA lots. MVA induced strong total (ELISA) and neutralizing (PRNT) antibody responses, with seroconversion rates of at least 99.5% after the second vaccination. Analogous findings were previously observed using the same MVA administration scheme [14,15,20–22], showing a reliable immunogenic potential.

This trial adds a large dataset of almost 2000 paired ELISA and PRNT titers to the immunogenicity database, exhibiting a significant correlation between total and neutralizing antibody titers that confirms the results of previous clinical trials [17]. Similarly, these results significantly enlarged the overall existing safety database of MVA. The addition of 3003 MVA vaccinated subjects, together with the 651 subjects from a recently completed phase II trial (publication in preparation), has doubled the size of the MVA safety database, i.e. cumulative safety data are now available from almost 8000 vaccinees.

Most of the AEs reported after MVA administration in this trial comprised temporary local and systemic reactions of mild to moderate intensity that did not require additional treatment nor led to withdrawal from further vaccination. As expected, the frequency of solicited AEs observed in the three MVA groups was significantly higher compared to the placebo group. Their frequency, intensity and duration were equally distributed across the 3 MVA groups, showing lot equivalence. This profile was similar to those established during the phase I and II clinical trial programs, further demonstrating the excellent and reliable safety of MVA across different populations [12, 13, 20–23].

Table 4. PRNT and ELISA GMTs, seroconversion rates and GMT group ratios 2 weeks after the second vaccination (PPS, n = 2549).

<table>
<thead>
<tr>
<th>PRNT and ELISA GMT and seroconversion rates</th>
<th>Group 1 (Lot 1) (n = 637)</th>
<th>Group 2 (Lot 2) (n = 628)</th>
<th>Group 3 (Lot 3) (n = 641)</th>
<th>Group 1–3 (n = 1906)</th>
<th>Group 4 (Placebo) (n = 643)</th>
</tr>
</thead>
<tbody>
<tr>
<td>GMT [95% CI] SC PRNT</td>
<td>110.7 [103.4, 118.4] 99.8%</td>
<td>110.5 [93.7, 107.8] 99.7%</td>
<td>117.2 [109.0, 126.0] 99.8%</td>
<td>109.3 [104.9, 113.8] 99.8%</td>
<td>1.0 [1.0, 1.1] 1.4%</td>
</tr>
<tr>
<td>ELISA</td>
<td>901.0 [844.8, 961.1] 99.7%</td>
<td>794.4 [738.1, 855.0] 99.5%</td>
<td>946.7 [888.2, 1008.9] 100.0%</td>
<td>878.9 [845.3, 913.8] 99.7%</td>
<td>1.1 [1.1, 1.3] 2.0%</td>
</tr>
</tbody>
</table>

**Group Ratios of PRNT and ELISA GMT**

<table>
<thead>
<tr>
<th>Group Ratio</th>
<th>Group 1/Group 2</th>
<th>Group 1/Group 3</th>
<th>Group 2/Group 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ratio of GMT [95% CI]</td>
<td>PRNT</td>
<td>ELISA</td>
<td>PRNT</td>
</tr>
<tr>
<td>Equivalence Met</td>
<td>1.0102 [0.9992, 1.2136] Yes</td>
<td>1.0134 [1.0288, 1.2505] Yes</td>
<td>Yes</td>
</tr>
<tr>
<td></td>
<td>0.9444 [0.8554, 1.0427] Yes</td>
<td>0.9518 [0.8695, 1.0419] Yes</td>
<td>0.8577 [0.7753, 0.9488] Yes</td>
</tr>
</tbody>
</table>

GMT: Geometric Mean Titer (for purposes of calculation titers below the detection limit are given the arbitrary value 1)
95% CI: 95% confidence interval [LCL = lower confidence limit and UCL = upper confidence limit]
SC: Seroconversion is the percentage of subjects who became seropositive or had an at least two-fold rise in titer from baseline
*: Equivalence is passed if the LCL > 1 / Delta and UCL < Delta. For the PRNT Delta is 2, i.e. CI must be contained in [1/2, 2]. For the ELISA Delta is 1.5, i.e. the CI must be contained in [2/3, 1.5].

[https://doi.org/10.1371/journal.pone.0195897.t004](https://doi.org/10.1371/journal.pone.0195897.t004)
Concerning unsolicited AEs, including SAEs, no trends towards any specific events or system organ classes were observed. The overall number of unsolicited AEs and SAEs was low and the distribution was comparable across all treatment groups.

Replicating smallpox vaccines are associated with a series of cardiac AEs of inflammatory nature, such as myo/pericarditis. MVA has exhibited a lack of such effects in almost 8000 vaccinees [6, 24]. A lower incidence of AESI was observed in the present study compared to previous trials, with no significant difference between the MVA and placebo groups. No signs of cardiac inflammatory disorders were detected in the 3003 subjects treated with MVA. A single case of chest pain that worsened when lying down occurred during the trial, meeting the protocol criteria for possible acute pericarditis. However, thorough cardiac examinations revealed normal ECG results without pericardial effusion and normal Troponin I levels. This event was therefore assessed as unlikely related to MVA and resolved spontaneously with no sequelae. These findings are in line with previous studies, suggesting a robust cardiac safety profile [12, 13].

Only three of the 3003 MVA-vaccinates showed an increase of Troponin I above normal limit following vaccination. One subject exhibited an elevated Troponin I value at baseline that did not classify as an AESI and therefore met the inclusion criterion for enrolment. This value later increased above baseline levels. The second subject showed increased Troponin I levels upon the second visit (14 days after the first vaccination), accompanied by normal ECG results. His Troponin I levels returned to normal 5 days later. The event was considered as resolved and assessed as unlikely related to the trial vaccine. The third subject had elevated Troponin I levels 15 days after vaccination. Further cardiac examination revealed signs suggesting athlete’s heart, which coincided with a history of marathon running. The event was later considered as resolved and assessed as unlikely related to trial vaccine. In summary, the frequency of Troponin I increase above ULN following MVA administration was below 1 in 1000.

All AESI were transient without long-term cardiac damage according to the cardiology follow-up examinations. AESI reports were based on findings obtained through the targeted examinations including Troponin I testing and ECG readings. Epidemiologic figures for background incidence of Troponin I elevations are in the range of 0.43% to 1.5%, depending on the definition of the upper limit of normal [25–27]. The background incidence of pericarditis shows a frequency of up to 27.7 cases per 100,000 patients [28]. The incidence for all AESI reported in this trial is thus in line with or below the published background incidence rates for otherwise healthy populations, suggesting that MVA administration presents no increased cardiac risk to recipients.

This phase III trial further demonstrates the favorable cardiac safety profile of the non-replicating smallpox vaccine MVA. Replication-competent smallpox vaccines such as Dryvax and ACAM2000 are associated with a significant risk of myo-/pericarditis [6–10, 29], with incidence rates ranging from 1 in 175 to 1 in 216 vaccinees following vaccination [29, 30]. A recent prospective surveillance study reported a significant increased risk to develop cardiovascular symptoms such as chest pain (approx. 1 in 12 vaccinees) and dyspnoea (approx. 1 in 19 vaccinees) after receiving ACAM2000 [30]. In the present trial, isolated cases of chest pain/discomfort and dyspnoea were equally distributed between MVA and placebo groups, making unlikely any association between these symptoms and MVA.

The overall AE profile observed in this trial coincides with reports from previous trials [12, 13, 15, 17, 19–22].

In summary, this trial has confirmed the excellent safety and cardiac profile of MVA, clearly differentiating MVA from replicating smallpox vaccines. In addition, the robust immunogenicity displayed by the different lots indicates a reliable and consistent manufacturing process.
Supporting information

S1 File. Poster.
(PDF)

S2 File. Patents by Paul Chaplin.
(DOCX)

S3 File. Clinical trial protocol.
(PDF)

S4 File. CONSORT 2010 checklist.
(DOC)

Acknowledgments

Design and conduct of the trial were managed by Bavarian Nordic A/S and Chiltern. The assistance of the following team members is appreciated:

Elke Jordan, Claudia Burkhart, Monika Flür, Sanja Vidojkovic, Monika Seiberth, Jutta Müller, Nicole Baedeker, Robert Gruenert, Nico Bethge (all BN).

Doug Clendenon, Jennifer Wyona, Rebecca Lobery, Mary Bailey, Gaargi Patel, Jill Hall, Kristie Newton (all Chiltern)

We wish to gratefully acknowledge the trial participants and clinical trial sites that devoted their time and effort to this research endeavour.

The following Investigators and Clinical Trials Sites recruited subjects for this trial:

George Bauer, Benchmark Research, Metairie, LA; Glen Biddulph, Tanner Clinic, Layton, UT; Andrew P. Brockmyre, Holston Medical Group, Bristol, TN; Daniel Brune, Accelovance, Peoria, IL; Matthew Davis, Rochester Clinical Research, Rochester, NY; Brandon Essink, Meridian Clinical Research, Omaha, NE; Steven Folkerth, Clinical Research Center of Nevada, Las Vegas, NV; David L. Fried, Omega Medical Research, Warwick, RI; Carl Griffin, Lynn Health Science Institute, Oklahoma City, OK; Wayne Harper, Wake Research Associates, Raleigh, NC; John M. Hill, Avail Clinical Research, Deland, FL; Eugene Huang, Therapeutics Clinical Research, San Diego, CA; Murray Kimmel, Accelovance, Melbourne, FL; Judith Kirstein, Advanced Clinical Research, West Jordan, UT; Steven J. Lawrence, Washington University in St. Louis, StLouis, MO; Kurt W. Lesh, Lynn Institute of the Rockies, Colorado Springs, CO; Andrew J. Lewin, National Research Institute, Los Angeles, CA; Maria Mascolo, Southeast Regional Research Group, Savannah, GA; Raymond Mason, Family Practice Center of Wooster, Wooster, OH; Richard Mills, PMG Research of Charleston, Mt. Pleasant, SC; Dennis N. Morrison, QPS Bio-Kinetic, Springfield, MO; Maurice Mufson, University Physicians & Surgeons, Huntington, WV; Teran Naccarato, Heartland Research Associates, Augusta, KS; Edgar T. Overton, Alabama Vaccine Research Clinic, Birmingham, AL; Terry Poling, Heartland Research Associates, Wichita, KS; Jamshid Saleh, Northern California Clinical Research Center, Redding, CA; William Seger, Benchmark Research, Fort Worth, TX; David J. Seiden, Broward Research Group, Hollywood, FL; William Smith, Volunteer Research Group, Knoxville, TN; Jimmie N. Tarro, Columbia Research Group, Portland, OR; Mark Turner, Advanced Clinical Research, Meridian, ID; Alan Wine, Rapid Medical Research, Cleveland, OH; Peter Winkle, Anaheim Clinical Trials, Anaheim, CA; Duane Wombolt, Clinical Research Associates of Tidewater, Norfolk, VA.

A poster about this trial with the title “A Clinical Phase III Trial Demonstrating Lot Consistency and Confirming Cardiac and Overall Safety of the Non-replicating Smallpox Vaccine MVA-BN” was presented at the 14th ASM Biodefense and Emerging Diseases Research Meeting in Arlington VA, February 8–10, 2016.
Author Contributions

Conceptualization: Eva Wagner, Siegfried Rösch.

Data curation: Philip Young.

Formal analysis: Philip Young.

Funding acquisition: Nathaly Samy, Paul Chaplin.

Investigation: Edgar Turner Overton, Steven J. Lawrence.

Methodology: Darja Schmidt, Christian Kreusel, Sonja De Carli, Thomas P. Meyer.

Project administration: Eva Wagner, Katrin Nopora.


Validation: Thomas P. Meyer.

Writing – original draft: Eva Wagner, Katrin Nopora, Philip Young, Darja Schmidt, Heinz Weidenthaler.

Writing – review & editing: Edgar Turner Overton, Steven J. Lawrence, Eva Wagner, Katrin Nopora, Siegfried Rösch, Philip Young, Darja Schmidt, Thomas P. Meyer, Heinz Weidenthaler, Nathaly Samy, Paul Chaplin.

References


